Continuous Glucose Monitoring in Critically Ill Patients
Information source: Medical University of Vienna
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Critical Illness
Intervention: continuous subcutaneous glucose monitoring (Device); continuous subcutaneous glucose monitoring (Device)
Phase: N/A
Status: Completed
Sponsored by: Medical University of Vienna Official(s) and/or principal investigator(s): Ulrike Holzinger, MD, Principal Investigator, Affiliation: Medical University of Vienna, Department of Medicine III
Summary
The purpose of this study is to determine whether subcutaneous continuous glucose monitoring
in critically ill patients is clinically feasible accurate and reliable.
Clinical Details
Official title: Accuracy and Reliability of Continuous Glucose Monitoring in Critically Ill Patients With Shock Requiring Norepinephrine Therapy
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Primary outcome: correlation of continuous glucose monitoring derived glucose values and arterial blood glucose measurements in critically ill patients with and without shock
Secondary outcome: influence of norepinephrine therapy, body mass index, severity of Illness (APACHE III, SAPS II) and blood glucose level on correlation
Detailed description:
Hyperglycemia is is associated with more complications and higher morbidity and mortality in
critically ill patients. Therefore, strict glycemic control with a target blood glucose
level between 80 and 110 mg/dl is recommended. Intensive insulin therapy requires continuous
intravenous insulin infusion according to an algorithm and frequent blood glucose
measurements. Implementation of intensive insulin therapy increases workload for both
physicians and especially for nurses.
Continuous glucose measurement would facilitate blood glucose control in critically ill
patients. Numerous studies have shown accuracy of the subcutaneous continuous glucose
monitoring derived glucose values compared to blood glucose measurements in diabetics.
Studies evaluating the subcutaneous continuous glucose monitoring in an inpatient-population
especially in an ICU-setting are rare. Therefore the aim of this study is the prospective
evaluation of continuous subcutaneous glucose monitoring in critically ill patients with
circulatory shock demanding norepinephrine therapy as compared to critically ill patients
without shock.
Eligibility
Minimum age: 19 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Admitted patients expected to stay >48h either with circulatory shock requiring
norepinephrine therapy or without circulatory shock.
Exclusion Criteria:
- Admitted patients expected to stay <48h
Locations and Contacts
Medical University of Vienna, Vienna 1090, Austria
Additional Information
Starting date: April 2005
Last updated: February 19, 2008
|